Melanocortin Peptides: PT-141, Melanotan-II, and What Receptor Research Reveals

The term “melanocortin” is most often associated with tanning and pigmentation. The history of research into the melanocortin system did indeed begin with melanocytes. However, today, this single receptor family encompasses molecules with very different effects, regulatory statuses, and roles in medicine and science.

PT-141 is an approved prescription drug. Melanotan 2 is an unapproved injectable compound that regulators have explicitly flagged as posing risks. They share a common biological basis, but virtually everything else sets them apart. Therefore, in this informational article, we want to examine them separately so that people can understand that they are not interchangeable variants of the same topic.

⚠️ This material is for educational purposes only. The compounds mentioned below differ fundamentally in their regulatory status: some are approved prescription drugs, while others are unapproved injectable substances with documented warnings from regulatory agencies. Nothing in this text constitutes a recommendation for use. Consult a doctor for any clinical questions.

The Melanocortin Receptor System

To understand why molecules from the same class have such different effects, we need to start with the receptors.

The melanocortin system includes five receptors: MC1R through MC5R. All of them are activated by similar ligands (POMC derivatives), but are expressed in different tissues and trigger different physiological responses. This is precisely why the same “class” of molecules can simultaneously affect pigmentation, energy metabolism, immune function, and neurobiological processes.

PT-141 acts primarily through MC3R and MC4R, which are expressed in the central nervous system. Melanotans, in turn, act through MC1R in melanocytes, although their receptor selectivity varies. MC1R stimulates melanogenesis; MC3R and MC4R act through entirely different pathways.

Moreover, in this case, this is not a technical detail. In fact, the receptor profile determines the entire subsequent effect. Moreover, that is precisely why “melanocortin peptide” is a category that requires clarification, not generalization.

PT-141 (Bremelanotide): An Approved Melanocortin Agonist

It is important to start with the fact that is often overlooked in discussions: PT-141 peptide and bremelanotide are the same molecule. It is an approved prescription drug in the United States (remember that a prescription drug should only be used under the supervision of a specialist. Any self-medication carries the risk of irreversible consequences for your health). Under the brand name Vyleesi, it was approved by the FDA in 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.

This is a crucial point. In this context, PT-141 peptide is neither an investigational compound nor an “alternative” molecule. It is an approved drug with a specific indication, a specific route of administration, and evidence base from clinical trials.

Its mechanism of action involves the activation of melanocortin receptors in the central nervous system (primarily MC3R and MC4R). Unlike drugs that act on the vascular system, bremelanotide acts through CNS-mediated pathways, making it pharmacologically distinct from previous approaches in this field. The clinical trials underlying the approval have been published – in particular, the study by Simon and colleagues in The Journal of Sexual Medicine.

How PT-141’s Mechanism Differs from Tanning Peptides

This is precisely where the receptor framework described above becomes practically useful.

PT-141 acts on MC3R and MC4R in the brain via receptors that are not directly related to pigmentation. In their original research context, melanotan primarily target MC1R in melanocytes (a peripheral receptor that triggers melanin synthesis).

These are not the same molecule at different doses. They have distinct receptor profiles and physiological effects. The fact that both classes are called “melanocortin” stems from their shared biochemical family, not from similarities in their mechanisms of action. Understanding this distinction is essential for correctly interpreting any literature on the subject.

Melanotan 2: An Unapproved Injectable

A clear distinction must be made here, because it is precisely the lack of such a distinction in the public sphere that creates problems.

Melanotan 2 is a synthetic analog of α-MSH with a broader receptor profile than Melanotan 1. Mechanistically, it activates MC1R (pigmentation) and MC3R and MC4R, which account for a range of systemic effects that extend far beyond melanogenesis.

It is critically important to note that melanotan 2 peptide has not been approved by the FDA, the EMA, or any other major regulatory agency. The European Medicines Agency issued a direct warning as early as 2009. Documented adverse effects include nausea, changes in mole pigmentation, priapism, and cardiovascular effects. The latter is particularly significant: the non-selective activation of melanocortin receptors upon systemic administration is not the same as a targeted therapeutic effect.

This section is included precisely because melanotan 2 regularly appears alongside approved drugs in search results. This proximity in search results does not reflect any similarity in regulatory status or safety.

Melanotan 1 vs. 2

Distinguishing between melanotan 1 and 2 is important because popular descriptions often conflate them (or, out of ignorance, confuse them), even though their regulatory statuses are fundamentally different.

Melanotan 1 is a synthetic melanocortin peptide , which is approved as a drug. Under the brand name Scenesse, it is approved in the EU and the U.S. for the prevention of phototoxic reactions in erythropoietic protoporphyria (a rare inherited disorder). Its clinical evidence was established in controlled trials in a specific population and indication.

Melanotan 2 is a different molecule. It is not approved. It is not an off-label use of afamelanotide. These are two different compounds with different receptor profiles and fundamentally different regulatory statuses. Any discussion that treats them as “option 1 and option 2 of the same thing” is terminologically incorrect.

Research vs. Marketing Claims Across These Compounds

If we rank the three compounds in this review by evidence, the picture becomes very uneven.

PT-141/bremelanotide is the only one of them with completed clinical trials, regulatory approval, and an established safety profile for a specific indication. This does not mean that it is suitable for everyone or risk-free. Its use must be under medical supervision, based on real-world data.

Afamelanotide (Melanotan 1) is similar: it is approved, well-documented, and used in a narrow, specific population.

Melanotan 2 is a different story. Research publications exist, and their mechanism has been studied in preclinical studies. However, there is a huge gap between “mechanism studied” and “safe and effective for use” – a gap that the regulatory process exists precisely to bridge in a controlled manner. MT2 has not gone through this process. Marketing claims surrounding it deliberately ignore this gap.

PT 141 has an approved indication and clinical data. MT2 has a mechanism of action and preclinical data, but no approval. It carries regulatory warnings and has no established safety profile in humans.

Key Takeaways and Safety

Here are a few key points to keep in mind when dealing with this topic: Regarding safety, MT2 does not have an established human safety profile sufficient to draw any conclusions. Documented adverse events exist. This is not a topic for self-experimentation outside of a clinical context.

• PT-141 (bremelanotide, Vyleesi): an approved prescription drug with a specific indication. It is used under medical supervision. It is not an investigational compound.
• Afamelanotide (Melanotan 1): also approved, but for a rare disease, not for tanning.
• Melanotan 2: an unapproved injectable compound with explicit warnings from regulatory agencies. The lack of approval here is not a mere formality but reflects a genuine gap in safety data.
• Belonging to the same receptor class does not mean the compounds are identical or that they carry the same risks.

Any use of these compounds, in any context, should be discussed with a doctor, not based on review articles.

In the Grey Research Peptides catalog, PT-141 10mg and Melanotan-II 10mg are available exclusively for in vitro laboratory use by qualified professionals. Not for use in humans or animals.